ITIF Search

Life Sciences

Innovation is essential to promoting human health, agricultural productivity, and ecological sustainability. ITIF’s Center for Life Sciences Innovation conducts research supporting advances in human biotechnology; pharmaceuticals; and health care policy outside the realm of IT.


How Japan Squandered Its Biopharmaceutical Competitiveness: A Cautionary Tale

How Japan Squandered Its Biopharmaceutical Competitiveness: A Cautionary Tale

Stringent drug price controls have significantly hampered the competitive and innovative capacity of Japan’s biopharmaceutical industry in recent decades, serving as a warning for U.S. policymakers considering introducing Medicare Part D drug price controls in 2022.

Testimony to the Senate Finance Committee on “Prescription Drug Price Inflation”

Testimony to the Senate Finance Committee on “Prescription Drug Price Inflation”

Expenditures for retail prescriptions have been roughly stable for the past two decades as a share of total U.S. health-care expenditures. Instead of applying broad price controls, policymakers should promote affordability and mitigate out-of-pocket costs for individuals.

More Publications and Events

October 13, 2022|Presentations

Lessons From Mexico’s Life Sciences Innovation Ecosystem for Indonesia

Stephen Ezell joins the program at HigherHeight 2022, hosted by Pfizer Indonesia and the Indonesian Biotechnology Study Program Association (IPSBI), to discuss what Indonesia can learn from Mexico’s experiences in building up its life sciences innovation ecosystem.

August 9, 2022|Press Releases

Reconciliation Bill Detrimental for U.S. Life Sciences Innovation, Says ITIF

The Inflation Reduction Act of 2022 incorporates unnecessary and unwarranted drug price controls that will harm America’s life-sciences innovation industry and deter biomedical innovation.

August 5, 2022|Blogs

Senate Reconciliation Legislation Fails to Reconcile the Interests of Biomedical Innovation and Drug Price Affordability

The bill fails to recognize three critical realities: 1) that drug prices are, in fact, not a significant driver of raging inflation; 2) that there exist better mechanisms to reform Medicare Part D drug pricing practices; 3) that mandated government price controls do inflict serious harm on nations’ life-sciences innovation systems.

August 1, 2022|Podcasts

Podcast: Life Sciences Innovation Through the Bayh-Dole Act, With Joe Allen

Rob and Jackie sat down with Joe Allen, who served as a professional staffer on the U.S. Senate Judiciary Committee to former Senator Birch Bayh, to discuss the importance of the Bayh-Dole Act and the future of life sciences innovation.

July 8, 2022|Blogs

Senate Democrats’ Drug Price Proposal Would Slow the Pace of New Drug Discovery

Congress should ignore pressure from progressive activists who want to use drug price controls to move to a government-led drug discovery and production system and instead focus on more pragmatic reforms.

June 24, 2022|Blogs

Postmortem on a Pyrrhic Victory for IP Foes at the WTO

The WTO’s approval of a TRIPS waiver for IP related to COVID-19 vaccines is essentially a shotgun blast completely missing the broadside of a barn.

June 17, 2022|Blogs

No, America’s Drug Prices Aren’t Climbing Radically Out of Control

The United States uniquely leads the world in innovating new drugs and getting them to patients first while sustaining a globally competitive industry and over time making drugs affordable by incentivizing competition and creating generic pathways.

June 10, 2022|Blogs

USG Remains Misguided in Endorsing COVID-19 TRIPS IPR Waiver

Instead of conflicting mandates, the Biden administration should articulate a coherent set of policies recognizing that IP represents a fundamental and distinguishing driver of American innovation and technological competitiveness. Support for the TRIPS COVID-19 IPR waiver cannot be consonant with such an agenda.

April 27, 2022|Events

Innovation and IP’s Role in Combatting the Covid-19 Pandemic

ITIF and the Center for Strategic and International Studies hosted two expert panels exploring how innovation and IP have proved to be instrumental in overcoming the COVID pandemic.

March 29, 2022|Events

How Using March-in Rights Would Threaten America’s Research Universities

ITIF hosted a panel discussion with leading experts on innovation policy, technology transfer, and business, who spoke to the practical implications of exercising federal “march-in” rights and why it would be a grave and ill-timed mistake for the U.S. health, competitiveness, and research landscape.

Back to Top